Full Press Release Details
NeuroSense Therapeutics Reports Positive Preliminary
Results from Novel Alzheimer's Biomarker Study
CAMBRIDGE, Mass., June 30, 2022 /PRNewswire/
-- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative
diseases, today announced results from a biomarker study conducted to evaluate the potential of CogniC, NeuroSense's combination drug
for the treatment of Alzheimer's disease (AD).
NeuroSense's biomarker study identified several biomarkers
associated with AD, which indicate CogniC's mechanism of action may be effective in targeting the pathways involved in the disease, such
as miRNA dysregulation, lysosomal dysfunction, and impaired autophagy. Additionally, hallmarks of AD were detected, such as increased
levels of amyloid- (A ) and intracellular aggregates of tau protein among the panel of biomarkers evaluated.
Preliminary results revealed high levels of TDP-43
in people who suffer from AD, when compared to the healthy control group. These findings provide additional support for TDP-43 pathology
as an integral part of AD, reinforcing the growing body of evidence in AD research regarding the role of TDP-43 in neurodegenerative pathologies. TDP-43
has been found in up to 57% of AD cases and aggregates of TDP-43 have been shown to be cytotoxic both in vitro and in
vivo.[1] NeuroSense's platform combination therapy technology, the basis of CogniC, has already shown to impact TDP-43
in a Phase IIa clinical trial biomarker study in another neurodegenerative disease, amyotrophic lateral sclerosis (ALS).
"Having identified these promising biomarkers,
which have the potential to be modulated by CogniC, we are now preparing to carry out a clinical proof-of-concept study in conjunction
with a leading AD clinic. The study is expected to commence in 2023," stated NeuroSense CEO, Alon Ben-Noon.
NeuroSense is conducting its AD biomarker study via
utilization of Neuron-Derived Exosomes (NDE), a cutting-edge technology which allows one to observe key alterations in biomarkers found
in the central nervous system in a non-invasive manner via collection of blood samples. Following further analysis, NeuroSense expects
to share more detailed results on additional novel biomarkers that were evaluated in this study through scientific conferences and peer-reviewed
Transactive response DNA binding protein of 43
kDa (TDP-43) is involved in regulation of gene expression. AD patients with TDP-43 pathology have increased severity of cognitive impairment
compared to those without TDP-43 pathology. Additionally, the strongest genetic risk factor for AD, apolipoprotein E4 (APOE4),
is associated with increased frequency of TDP-43 pathology.[1]
[1] Meneses, A., Koga, S., O'Leary,
J. et al. TDP-43 Pathology in Alzheimer's Disease. Mol Neurodegeneration 16, 84 (2021). https://doi.org/10.1186/s13024-021-00503-x
About Alzheimer's Disease
Alzheimer's disease (AD) is a brain disorder that
slowly destroys memory and thinking skills. AD is the most common cause of dementia, a general term for memory loss and other cognitive
abilities serious enough to interfere with daily life. Alzheimer's disease accounts for 60-80% of dementia cases. The global AD treatment
market is expected to grow to $5 billion in 2022.
CogniC is a combination drug for the treatment of
Alzheimer's disease and is based on NeuroSense's combination platform technology. The lead drug candidate in that platform is PrimeC,
which is currently being evaluated in a Phase IIb study for the treatment of amyotrophic lateral sclerosis (ALS).
NeuroSense Therapeutics, Ltd. is a clinical-stage
biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases.
NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease,
among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available
for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of
related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
For additional information, we invite you to visit
Forward-Looking Statements
This press release contains "forward-looking
statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained
in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by
the use of words such as "anticipate," "believe," "contemplate," "could," "estimate,"
"expect," "intend," "seek," "may," "might," "plan," "potential,"
"predict," "project," "target," "aim," "should," "will" "would,"
or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking
statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions
that are difficult to predict and include statements regarding the company's CogniC development program; the potential for CogniC to safely
and effectively target AD; preclinical and clinical data for CogniC; the timing of current and future clinical trials; the nature, strategy
and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates
of the company. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate.
Forward-looking statements contained in this announcement are made as of this date, and NeuroSense Therapeutics Ltd. undertakes no duty
to update such information except as required under applicable law.
For further information: Email: info@neurosense-tx.com,
Tel: +972 (0)9 799 6183